BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2022 Earnings Conference Call March 9, 2023 8:30 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer & Founder
Matt Wiley - Chief Commercial Officer
Richard Steinhart - Chief Financial Officer
Rob Risinger - Chief Medical Officer, Neuroscience
Vincent O’Neill - Chief R&D Officer of OnkosXcel Therapeutics
Conference Call Participants
Colin Bristow - UBS
Robyn Karnauskas - Truist Securities
Greg Harrison - Bank of America
Graig Suvannavejh - Mizuho Securities
Sumant Kulkarni - Canaccord Genuity
Eddie Hickman - Guggenheim Partners
Corinne Jenkins - Goldman Sachs
Ram Selvaraju - H.C. Wainwright
Samir Devani - Rx Securities
Operator
Good morning, and welcome to the BioXcel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company.
Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2022 which can be found at www.BioXceltherapeutics.com or on www.sec.gov, and which will be updated in its Annual Report on Form 10-K for the year-end December 31, 2022. As a reminder, today's conference is being recorded.
Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Matt Wiley, Chief Commercial Officer; Dr. Vince O’Neill, Chief R&D Officer of OnkosXcel Therapeutics; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; and Dr. Frank Yocca, Chief Scientific Officer.
It is now my pleasure to turn the call over to Dr. Mehta, the CEO and Founder of BioXcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you, operator. Welcome everyone and thank you for joining our call today to discuss BioXcel Therapeutics fourth quarter and full year 2022 financial performance and business highlights. It was exactly 5 years ago that BioXcel Therapeutics became a public company, and we embarked on our journey with a clear mission to build a uniquely disruptive biopharmaceutical company model using artificial intelligence approaches to bring transformative medicines in neuroscience and immuno-oncology to patients.
We are proud of what we have accomplished. At the same time, we are even more excited about what lies ahead. And so it is with great pride and enthusiasm that I share with you why I believe the company has never been better positioned to potentially bring new treatment options to millions of patients in areas of high unmet need and deliver significant value to our shareholders.